This is the classic website, which will be retired eventually. Please visit the modernized ClinicalTrials.gov instead.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05338970
Recruitment Status : Active, not recruiting
First Posted : April 21, 2022
Last Update Posted : April 19, 2024
Sponsor:
Information provided by (Responsible Party):
Daiichi Sankyo

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
Disease progression is typical for patients with epidermal growth factor receptor mutated (EGFRm) non-small cell lung cancer (NSCLC). Standard platinum-based chemotherapy offers limited efficacy and an unfavorable safety profile.There is an urgent need for more effective and tolerable therapies for patients with EGFRm NSCLC who have exhausted available targeted therapies. Clinical evidence suggest that patritumab deruxtecan constitutes a promising investigational therapy for patients with EGFRm NSCLC.

Condition or disease Intervention/treatment Phase
Nonsquamous Non-small Cell Lung Cancer EGFR L858R EGFR Exon 19 Deletion Drug: Patritumab Deruxtecan Drug: Platinum-based chemotherapy Phase 3

Detailed Description:

Patritumab deruxtecan (HER3-DXd, U3-1402) is an antibody-drug conjugate (ADC) comprising an anti-HER3 mAb linked to a topoisomerase I inhibitor that is in clinical development for patients with NSCLC, metastatic breast cancer, and colorectal cancer.

The primary objective of the current study is to compare the efficacy of patritumab deruxtecan versus platinum-based chemotherapy, as measured by progression-free survival (PFS) and the key secondary endpoint of overall survival (OS), in participants with metastatic or locally advanced NSCLC with an EGFR-activating mutation (exon 19 deletion or L858R) after failure of third-generation (eg, osimertinib, lazertinib, aumolertinib, alflutinib) EGFR TKI therapy.

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 586 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 3, Randomized, Open-label Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced Epidermal Growth Factor Receptor-mutated (EGFRm) Non-small Cell Lung Cancer (NSCLC) After Failure of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) Therapy (HERTHENA-Lung02)
Actual Study Start Date : July 8, 2022
Estimated Primary Completion Date : August 30, 2024
Estimated Study Completion Date : June 30, 2026

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Patritumab deruxtecan
Participants who will be randomized to receive patritumab deruxtecan (HER3-DXd) 5.6 mg/kg q3W.
 Drug: Patritumab Deruxtecan
Intravenous administration, 5.6 mg/kg every 3 weeks (q3W)
Other Names:
  • HER3-DXd
  • U3-1402
Active Comparator: Platinum-based chemotherapy
Participants who will be randomized to receive platinum-based chemotherapy for 4 cycles: pemetrexed plus either cisplatin or carboplatin. Participants without disease progression after 4 cycles of platinum plus pemetrexed therapy may continue treatment with maintenance pemetrexed with no restriction on the number of cycles.
 Drug: Platinum-based chemotherapy
Intravenous, pemetrexed 500 mg/m^2 plus either cisplatin (75 mg/m^2) or carboplatin (target area under the plasma concentration time curve of 5 [AUC5] by using the Calvert formula) q3W


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Progression-free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR) Based on RECIST v1.1 [ Time Frame: Baseline up to approximately 49 months ]
    Progression-free survival (PFS) is defined as the time from the date of randomization to the earlier of the dates of the first documentation of objective progression of disease or death due to any cause.


Secondary Outcome Measures :
  1. Overall Survival (OS) [ Time Frame: Baseline up to approximately 49 months ]
    Overall survival (OS) is defined as the time from the date of randomization to the date of death due to any cause.

  2. Progression-free Survival (PFS) as Assessed by Investigator Review Based on RECIST v1.1 [ Time Frame: Baseline up to approximately 49 months ]
    Progression-free survival (PFS) is defined as the time from the date of randomization to the earlier of the dates of the first documentation of objective progression of disease or death due to any cause.

  3. Progression-free Survival (PFS) as Assessed by Local Standard Clinical Practice [ Time Frame: Baseline up to approximately 49 months ]
    Progression-free survival (PFS) by local standard clinical practice is defined as the time from date of randomization to the documented progression on the first new anticancer therapy (if administered) or death due to any cause, whichever occurred first.

  4. Objective Response Rate (ORR) as Assessed by BICR and Investigator Review Based on RECIST v1.1 [ Time Frame: Baseline up to approximately 49 months ]
    Objective response rate (ORR) is defined as the proportion of participants who have a confirmed best overall response (BOR) of complete response (CR) or partial response (PR).

  5. Duration of Response (DoR) as Assessed by BICR and Investigator Review Based on RECIST v1.1 [ Time Frame: Baseline up to approximately 49 months ]
    Duration of response (DoR) is defined as the time from the first documentation of objective response (CR or PR) to the earlier of the dates of the first documentation of objective progression of disease or death due to any cause.

  6. Clinical Benefit Rate (CBR) as Assessed by BICR and Investigator Review Based on RECIST v1.1 [ Time Frame: Baseline up to approximately 49 months ]
    Clinical benefit rate (CBR) will be assessed by BICR and Investigator based on RECIST v1.1. CBR is defined as the proportion of participants who have a confirmed BOR of CR, PR, or stable disease (SD) that lasts for at least 180 days.

  7. Disease Control Rate (DCR) as Assessed by BICR and Investigator Review Based on RECIST v1.1 [ Time Frame: Baseline up to approximately 49 months ]
    Disease control rate (DCR) is defined as the proportion of participants who have a confirmed BOR of CR, PR, or SD.

  8. Time to Response (TTR) as Assessed by BICR and Investigator Review Based on RECIST v1.1 [ Time Frame: Baseline up to approximately 49 months ]
    Time to response (TTR) is defined as the time from the date of randomization to the date of the first documentation of response (CR or PR) that is subsequently confirmed.

  9. Intracranial PFS as Assessed by BICR [ Time Frame: Baseline up to approximately 49 months ]
    Intracranial PFS is defined as the time from the date of randomization to the earlier of the dates of the first documented radiographic intracranial disease progression or death, whichever comes first, as assessed by BICR per CNS-RECIST, in participants with CNS lesion(s) at baseline by BICR per CNS-RECIST.

  10. Mean Change from Baseline in Non-small Cell Lung Cancer - Symptom Assessment Questionnaire [ Time Frame: Baseline up to approximately 49 months ]
    The NSCLC-SAQ will assess disease-related symptom change in patients with NSCLC.

  11. Mean Change from Baseline in Patient's Global Impression of Change [ Time Frame: Baseline up to approximately 49 months ]
    The PGI-C is a 7-point scale depicting a participant's rating of overall improvement.

  12. Mean Change from Baseline in Patient's Global Impression of Severity [ Time Frame: Baseline up to approximately 49 months ]
    The PGI-S is a one-item questionnaire that contains six response options.

  13. Mean Change from Baseline in Patient's Global Impression of Treatment Tolerability [ Time Frame: Baseline up to approximately 49 months ]
    The PGI-TT will capture the patient's overall impression of treatment tolerability.

  14. Mean Change from Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQ-C30) [ Time Frame: Baseline up to approximately 49 months ]
    The EORTC-QLQ-C30 will assess the patient's overall quality of life (QoL).

  15. Mean Change from Baseline in EuroQol Questionnaire-5 dimensions-5 levels (EQ-5D-5L) [ Time Frame: Baseline up to approximately 49 months ]
    The EQ-5D-5L is a standardized instrument that will be used for measuring generic health status required for health technology assessments.

  16. Number of Participants With Treatment-emergent Adverse Events (TEAEs) [ Time Frame: Baseline up to approximately 49 months ]
    TEAEs will be graded by using National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0.

  17. Percentage of Participants Who Are Anti-Drug Antibody (ADA)-Positive (Baseline and Post-Baseline) [ Time Frame: Baseline up to approximately 49 months ]
    The immunogenicity of patritumab deruxtecan will be confirmed by assessing the anti-drug antibodies.

  18. Percentage of Participants Who Have Treatment-emergent ADA [ Time Frame: Baseline up to approximately 49 months ]
    The immunogenicity of patritumab deruxtecan will be confirmed by assessing the anti-drug antibodies.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Is a male or female subject aged ≥18 years (follow local regulatory requirements if the legal age of consent for study participation is >18 years old).
  2. Has histologically or cytologically documented metastatic or locally advanced non-squamous NSCLC not amenable to curative surgery or radiation.
  3. Has documentation of an EGFR-activating mutation detected from tumor tissue or blood sample: exon 19 deletion or L858R at diagnosis or thereafter.
  4. Received 1 or 2 prior line(s) of an approved EGFR TKI treatment in the metastatic or locally advanced setting, which must include a third -generation EGFR TKI
  5. May have received either neoadjuvant and/or adjuvant treatment if progression to metastatic or locally advanced disease occurred at least 12 months after the last dose of such therapy and subsequently experienced disease progression on or after third-generation EGFR TKI treatment administered in the metastatic or locally advanced setting.
  6. Has not received any other prior systemic therapies in the metastatic or locally advanced setting (including chemotherapy, immunotherapy etc) (even if administered in combination with EGFR TKI).
  7. Has documentation of radiographic disease progression while receiving or after receiving a third generation EGFR TKI for metastatic or locally advanced disease.
  8. Has at least 1 measurable lesion as per RECIST v1.1 by Investigator assessment.
  9. Is willing to have a tumor biopsy or provide recently obtained tumor tissue.
  10. Has an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1 at Screening.

  11. Has adequate bone marrow reserve and organ function based on local laboratory evaluation within 14 days prior to randomization:

    • Platelet count: ≥100,000/mm^3 or ≥100 × 10^9/L within 14 days prior to the assessment of platelet count during the Screening Period
    • Absolute neutrophil count: ≥1500/mm^3 or ≥1.5 × 10^9/L within 14 days prior to the assessment of absolute neutrophil count during the Screening Period
    • Hemoglobin (Hgb): ≥9.0 g/dL within 14 days prior to the assessment of hemoglobin during the Screening Period
    • Creatine clearance (CrCl): CrCl ≥45 mL/min calculated by using the Cockcroft-Gault equation or measured CrCl
    • Aspartate aminotransferase (AST)/Alanine aminotransferase (ALT): AST/ALT ≤3× Upper limit of normal (ULN)
    • Total bilirubin (TBL): TBL ≤1.5 × ULN
    • Serum albumin: ≥2.5 g/dL
    • Prothrombin time (PT) or Prothrombin time-International normalized ratio (PT-INR) and activated partial thromboplastin time (aPTT)/partial thromboplastin time (PTT): ≤1.5 × ULN, except for participants receiving coumarin-derivative anticoagulants or other similar anticoagulant therapy who must have PT-INR within therapeutic range as deemed appropriate by the Investigator

Exclusion Criteria:

  1. Has any previous histologic or cytologic evidence of small cell OR combined small cell/non-small cell disease in the archival tumor tissue or pretreatment tumor biopsy, or squamous NSCLC histology
  2. Has any history of interstitial lung disease (ILD) (including pulmonary fibrosis or radiation pneumonitis), has current ILD, or is suspected to have such disease by imaging during Screening

  3. Has clinically severe respiratory compromise (based on the Investigator's assessment) resulting from intercurrent pulmonary illnesses including, but not limited to the following:

    • Any underlying pulmonary disorder, restrictive lung disease, or pleural effusion
    • Any autoimmune, connective tissue, or inflammatory disorders where there is documented, or a suspicion of pulmonary involvement at the time of Screening
    • OR prior complete pneumonectomy
  4. Is receiving chronic systemic corticosteroids dosed at >10 mg prednisone or equivalent anti-inflammatory activity or any form of immunosuppressive therapy prior to randomization
  5. Has any history of or evidence of current leptomeningeal disease
  6. Has evidence of clinically active spinal cord compression or brain metastases, defined as being symptomatic and untreated, or requiring therapy with corticosteroids or anticonvulsants to control associated symptoms
  7. Any prior treatment with any agent including an antibody drug conjugate (ADC) containing a chemotherapeutic agent targeting topoisomerase I, human epidermal growth factor receptor 3 (HER3) antibody, and any systemic therapies (other than EGFR TKIs) in the metastatic/locally advanced setting, including chemotherapy or any other systemic therapy in combination with an EGFR TKI
  8. Has history of other active malignancy within 3 years prior to randomization, except for adequately resected nonmelanoma skin cancer, adequately treated intraepithelial carcinoma of the cervix, and any other curatively treated in situ disease
  9. Has uncontrolled or significant cardiovascular disease prior to randomization
  10. Has active hepatitis B and/or hepatitis C infection, such as those with serologic evidence of active viral infection within 28 days of randomization
  11. Has a known human immunodeficiency virus (HIV) infection that is not well controlled
  12. Has clinically significant corneal disease
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05338970


Locations
Show Show 182 study locations
Sponsors and Collaborators
Daiichi Sankyo
Investigators
Layout table for investigator information
Study Director: Global Clinical Leader Daiichi Sankyo
Study Chair: Clinical Scientist Daiichi Sankyo
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Daiichi Sankyo
ClinicalTrials.gov Identifier: NCT05338970    
Other Study ID Numbers: U31402-A-U301
2021-005879-40 ( EudraCT Number )
jRCT 2021220002 ( Other Identifier: JAPIC )
First Posted: April 21, 2022    Key Record Dates
Last Update Posted: April 19, 2024
Last Verified: April 2024
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Clinical Study Report (CSR)
Time Frame: Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.
Access Criteria: Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.
URL: https://vivli.org/ourmember/daiichi-sankyo/

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Daiichi Sankyo:
Nonsquamous Non-small Cell Lung Cancer
EGFR L858R
EGFR exon 19 deletion
 Patritumab deruxtecan
HER3-DXd
U3-1402
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
 Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Patritumab deruxtecan
Antineoplastic Agents, Immunological
Antineoplastic Agents